Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 5848 | 7.33 |
09:43 ET | 8289 | 7.27 |
09:45 ET | 1428 | 7.24 |
09:48 ET | 1180 | 7.185 |
09:50 ET | 100 | 7.22 |
09:54 ET | 150 | 7.22 |
09:56 ET | 750 | 7.27 |
10:03 ET | 100 | 7.26 |
10:06 ET | 1758 | 7.29 |
10:10 ET | 1396 | 7.35 |
10:14 ET | 100 | 7.395 |
10:17 ET | 400 | 7.3896 |
10:21 ET | 300 | 7.36 |
10:24 ET | 100 | 7.36 |
10:26 ET | 2000 | 7.35 |
10:28 ET | 200 | 7.31 |
10:30 ET | 100 | 7.29 |
10:32 ET | 255 | 7.29 |
10:33 ET | 300 | 7.26 |
10:35 ET | 100 | 7.23 |
10:37 ET | 2099 | 7.265 |
10:39 ET | 438 | 7.18 |
10:44 ET | 1000 | 7.17 |
10:46 ET | 1825 | 7.2 |
10:53 ET | 300 | 7.23 |
10:55 ET | 2300 | 7.2 |
11:09 ET | 100 | 7.22 |
11:11 ET | 1800 | 7.15 |
11:15 ET | 500 | 7.13 |
11:18 ET | 200 | 7.14 |
11:22 ET | 3160 | 7.17 |
11:24 ET | 100 | 7.16 |
11:26 ET | 1075 | 7.16 |
11:29 ET | 100 | 7.15 |
11:31 ET | 2161 | 7.14 |
11:33 ET | 600 | 7.14 |
11:36 ET | 100 | 7.14 |
11:40 ET | 700 | 7.18 |
11:42 ET | 700 | 7.1642 |
11:44 ET | 613 | 7.14 |
11:45 ET | 100 | 7.14 |
11:49 ET | 663 | 7.147 |
11:51 ET | 300 | 7.17 |
11:56 ET | 150 | 7.1633 |
11:58 ET | 200 | 7.2 |
12:02 ET | 964 | 7.21 |
12:09 ET | 1022 | 7.2137 |
12:12 ET | 500 | 7.2168 |
12:18 ET | 200 | 7.23 |
12:23 ET | 100 | 7.25 |
12:27 ET | 1800 | 7.28 |
12:30 ET | 100 | 7.285 |
12:32 ET | 3700 | 7.24 |
12:36 ET | 100 | 7.24 |
12:39 ET | 100 | 7.225 |
12:41 ET | 100 | 7.23 |
12:48 ET | 350 | 7.22 |
12:50 ET | 100 | 7.18 |
12:52 ET | 100 | 7.19 |
12:54 ET | 100 | 7.205 |
12:59 ET | 100 | 7.21 |
01:08 ET | 100 | 7.21 |
01:10 ET | 100 | 7.22 |
01:14 ET | 100 | 7.22 |
01:21 ET | 100 | 7.19 |
01:24 ET | 518 | 7.19 |
01:26 ET | 3790 | 7.11 |
01:28 ET | 3575 | 7.16 |
01:30 ET | 465 | 7.1 |
01:32 ET | 3410 | 7.09 |
01:33 ET | 400 | 7.05 |
01:35 ET | 918 | 7.02 |
01:37 ET | 968 | 7.02 |
01:39 ET | 1975 | 7.02 |
01:42 ET | 100 | 7.025 |
01:44 ET | 1000 | 7.02 |
01:46 ET | 1100 | 7.0234 |
01:48 ET | 100 | 7.02 |
01:50 ET | 1165 | 7.04 |
01:51 ET | 1240 | 7.03 |
01:53 ET | 887 | 7.03 |
01:55 ET | 1059 | 7.05 |
02:00 ET | 100 | 7.055 |
02:04 ET | 100 | 7.055 |
02:06 ET | 200 | 7.07 |
02:08 ET | 200 | 7.065 |
02:11 ET | 100 | 7.065 |
02:13 ET | 500 | 7.09 |
02:15 ET | 500 | 7.09 |
02:18 ET | 1365 | 7.0801 |
02:20 ET | 800 | 7.11 |
02:22 ET | 1000 | 7.1 |
02:24 ET | 200 | 7.105 |
02:26 ET | 300 | 7.105 |
02:29 ET | 200 | 7.1 |
02:31 ET | 200 | 7.07 |
02:33 ET | 100 | 7.1 |
02:36 ET | 220 | 7.08 |
02:38 ET | 1652 | 7.06 |
02:42 ET | 500 | 7.085 |
02:45 ET | 300 | 7.06 |
02:47 ET | 128 | 7.085 |
02:49 ET | 900 | 7.06 |
02:54 ET | 100 | 7.0975 |
02:58 ET | 100 | 7.085 |
03:00 ET | 2430 | 7.095 |
03:02 ET | 500 | 7.12 |
03:03 ET | 3900 | 7.125 |
03:05 ET | 2000 | 7.12 |
03:07 ET | 1200 | 7.09 |
03:09 ET | 3011 | 7.14 |
03:12 ET | 1500 | 7.19 |
03:14 ET | 600 | 7.165 |
03:16 ET | 200 | 7.19 |
03:18 ET | 900 | 7.19 |
03:20 ET | 200 | 7.165 |
03:21 ET | 200 | 7.165 |
03:23 ET | 500 | 7.165 |
03:25 ET | 3230 | 7.15 |
03:27 ET | 100 | 7.14 |
03:30 ET | 100 | 7.14 |
03:32 ET | 7516 | 7.215 |
03:34 ET | 300 | 7.215 |
03:36 ET | 900 | 7.2275 |
03:38 ET | 200 | 7.215 |
03:39 ET | 2064 | 7.23 |
03:41 ET | 11080 | 7.3 |
03:43 ET | 701 | 7.285 |
03:45 ET | 1024 | 7.27 |
03:48 ET | 2420 | 7.28 |
03:50 ET | 24245 | 7.41 |
03:52 ET | 780 | 7.385 |
03:54 ET | 500 | 7.325 |
03:56 ET | 2220 | 7.36 |
03:57 ET | 3783 | 7.38 |
03:59 ET | 7384 | 7.4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 220.4M | -4.3x | --- |
Rezolute Inc | 220.9M | -3.8x | --- |
Greenwich Lifesciences Inc | 222.3M | -24.0x | --- |
Zura Bio Ltd | 222.9M | -2.1x | --- |
Solid Biosciences Inc | 217.6M | -1.4x | --- |
ATAI Life Sciences NV | 222.7M | -5.5x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.4M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 2,721.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.